Physician profile
Ramon Ty
NPI 1861474595
$11,080.23
in general payments reported to CMS, 2019-2025
35 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,792 · 2020: $1,266 · 2021: $1,965 · 2022: $1,702 · 2023: $1,177 · 2024: $1,014 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.26 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,208.53 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $1,339.34 | 2019-2024 | Xarelto |
| Amgen INC. | $919.37 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $873.89 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $870.91 | 2019-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $837.97 | 2019-2023 | Avvigo Guidance System, Synergy |
| Abbott Laboratories | $726.39 | 2019-2025 | Aveir, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $434.78 | 2019-2023 | |
| Lilly USA, LLC | $374.48 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $352.21 | 2019-2025 | Wegovy |
| Esperion Therapeutics, INC. | $271.01 | 2020-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $264.80 | 2022 | |
| Medtronic, INC. | $174.07 | 2024 | Micra |
| Sanofi-Aventis U.S. LLC | $173.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $169.63 | 2019-2025 | Eliquis |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Ty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.